Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 828 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with... December 13, 2023 People with Cancer Say Access to Their Clinical Notes Is Valuable November 18, 2020 Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And... May 12, 2020 Mom Unknowingly Has Cancer For 3 Years After Doctor Keeps Telling... March 21, 2019 Load more HOT NEWS EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of... FDA Grants Accelerated Approval to Tovorafenib for Patients with Relapsed or... EMA Recommends Extension of Indications for Cabozantinib FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable...
